ES2153384T3 - Metodo para tratar la esclerosis multiple. - Google Patents

Metodo para tratar la esclerosis multiple.

Info

Publication number
ES2153384T3
ES2153384T3 ES93917954T ES93917954T ES2153384T3 ES 2153384 T3 ES2153384 T3 ES 2153384T3 ES 93917954 T ES93917954 T ES 93917954T ES 93917954 T ES93917954 T ES 93917954T ES 2153384 T3 ES2153384 T3 ES 2153384T3
Authority
ES
Spain
Prior art keywords
necrosis factor
tumour necrosis
multiple sclerosis
treat multiple
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917954T
Other languages
English (en)
Inventor
John Leslie Turk
David Baker
Marc Feldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology filed Critical Kennedy Institute of Rheumotology
Application granted granted Critical
Publication of ES2153384T3 publication Critical patent/ES2153384T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Transplanting Machines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UN METODO DE TRATAMIENTO DE ESCLEROSIS MULTIPLE, A TRAVES DE LA ADMINISTRACION DE UN ANTICUERPO DE FACTOR DE NECROSIS ANTI-TUMOR, DE UN RECEPTOR DE FACTOR DE NECROSIS DE TUMOR SOLUBLE O DE UN COMPUESTO CAPAZ DE BLOQUEAR LA PRODUCCION DEL FACTOR DE NECROSIS DE TUMOR, SUS EFECTOS Y/O TRANSDUCCION DE SEÑAL DE RECEPTOR DE FACTOR DE NECROSIS DE TUMOR. EL METODO PUEDE SER UTILIZADO PARA AYUDAR EN TERAPIA PARA HUMANOS Y OTROS MAMIFEROS.
ES93917954T 1993-07-30 1993-07-30 Metodo para tratar la esclerosis multiple. Expired - Lifetime ES2153384T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001614 WO1995003827A1 (en) 1993-07-30 1993-07-30 Method for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ES2153384T3 true ES2153384T3 (es) 2001-03-01

Family

ID=10729416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917954T Expired - Lifetime ES2153384T3 (es) 1993-07-30 1993-07-30 Metodo para tratar la esclerosis multiple.

Country Status (11)

Country Link
US (1) US5958409A (es)
EP (2) EP0710121B1 (es)
JP (1) JPH09509646A (es)
AT (1) ATE196849T1 (es)
AU (1) AU4719093A (es)
DE (1) DE69329558T2 (es)
DK (1) DK0710121T3 (es)
ES (1) ES2153384T3 (es)
GR (1) GR3035196T3 (es)
PT (1) PT710121E (es)
WO (1) WO1995003827A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6225300B1 (en) 1995-07-14 2001-05-01 Applied Research Systems Ars Holding Nv TNF receptor and steroid hormone in a combined therapy
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
CA2487039A1 (en) * 2001-06-11 2002-12-19 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
EP2409569B1 (en) * 2002-02-20 2017-08-16 Emisphere Technologies, Inc. Method for administering GLP-1 molecules
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
JP2009531295A (ja) * 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
WO1991002078A1 (en) * 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE4202665A1 (de) * 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
US5958409A (en) 1999-09-28
GR3035196T3 (en) 2001-04-30
EP1004312A1 (en) 2000-05-31
WO1995003827A1 (en) 1995-02-09
EP0710121A1 (en) 1996-05-08
JPH09509646A (ja) 1997-09-30
ATE196849T1 (de) 2000-10-15
PT710121E (pt) 2001-04-30
AU4719093A (en) 1995-02-28
DE69329558D1 (de) 2000-11-16
EP0710121B1 (en) 2000-10-11
DE69329558T2 (de) 2001-05-31
DK0710121T3 (da) 2001-02-05

Similar Documents

Publication Publication Date Title
ES2153384T3 (es) Metodo para tratar la esclerosis multiple.
PT871473E (pt) Utilizacao de il-10 para curar feridas com cicatrizacao reduzida
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
NO941780D0 (no) Fremgangsmåte for behandling av TNF-avhengig inflammasjon under anvendelse av tumornekrosefaktorantagonister
BR9508245A (pt) Método para inhibir metástase de cáncer por administração oral de pectina citrica modificada solúvel
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
NO901141D0 (no) Additiv og fremgangsmaate for behandling av underjordiske formasjoner.
DK71387A (da) Terapeutisk middel til behandling af psoriasis
GR3029490T3 (en) Use of leflunomid for the inhibition of tumor necrosis factor alpha.
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
ES2058343T3 (es) Piridinas disubstituidas.
MX170929B (es) Empleo de substancias antigenicas para la profilaxis o la terapia de transtornos y enfermedades en el conducto digestivo de animales y humanos
DE69220939D1 (de) Gegengift immunsera
DE59206872D1 (de) Verwendung von torasemid zur behandlung von hirnödemen
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
NO168177C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polysykliske forbindelser
AU6916587A (en) Laminated dressing
WO1993024117A3 (en) Medicaments for the treatment of anxiety
ES2236692T3 (es) Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas.
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
RO86650B1 (ro) Preparat farmaceutic pentru tratarea dermatozelor
ATE149832T1 (de) Verwendung von cromakalim/brl 38227 zur behandlung der überreaktivität der luftwege
EP0321094A3 (en) Treatment of factor viii inhibitors
SE9003704D0 (sv) New selenophen derivatives, a preparation process of the samme and therapeutical compositions containing them
ATE85750T1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19961121

FG2A Definitive protection

Ref document number: 710121

Country of ref document: ES